Combination treatment for HER2-mutated lung cancer after prior therapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two drugs together (SHR-A1811 and pertuzumab) to see if they can shrink or control lung cancer that has a HER2 change and has already been treated once before. It is a second-line option that targets the cancer specifically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread.
- Your cancer has a specific change (mutation, amplification, or overexpression) in the HER2 gene.
- You have already had at least one prior treatment for advanced cancer, but it is no longer working.
- You have at least one tumor that can be measured on scans and your overall health allows you to do daily activities.
- You do not have untreated or active brain metastases, and you have recovered from side effects of previous treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, SHR-A1811 and AK112, for people with advanced non-small cell lung cancer that has HER2 changes. It may help if you have not improved on standard treatment or if you have not yet had treatment.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.